Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Sales commission litigation for beverage container supplier
Represented a leading supplier of fridge packs and other beverage containers in litigation brought by a former sales representative claiming an more
Class action law suit involving commercial truck diesel engines
Represented defendant in class action involving alleged defects in commercial truck diesel engines with exposure in excess of $250,000,000. more
Financing of acquisition made by Reynolds American
Represented Reynolds American Inc. in obtaining $2.1 billion of credit facilities to finance its acquisition of the Conwood Company. more
Litigation over operating agreements and maintenance contracts for rail travel company
Represented a major rail travel company in suits over rail lines owned by the freight railroads in front of the National Arbitration Panel, a special more